FindTrial
Sign In

Molibresib

DRUG3 trials

Sponsors

GlaxoSmithKline, National Cancer Institute (NCI)

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III T-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV T-Cell Non-Hodgkin LymphomaMetastatic NUT CarcinomaRefractory B-Cell Non-Hodgkin Lymphoma

Phase 1

Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
WithdrawnNCT03925428
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma +14
Start: 2020-09-18End: 2020-09-18Updated: 2020-09-28
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma
WithdrawnNCT04116359
National Cancer Institute (NCI)Metastatic NUT Carcinoma, Unresectable NUT Carcinoma
Start: 2020-09-18End: 2020-09-18Updated: 2020-09-28

Unknown Phase

Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma
NCT03702036
GlaxoSmithKlineSolid Tumours
Updated: 2020-04-13